Simon Witzel
Overview
Explore the profile of Simon Witzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wiesenfarth M, Gunther K, Muller K, Witzel S, Weiland U, Mayer K, et al.
Brain Commun
. 2023 Apr;
5(2):fcad087.
PMID: 37006326
An expansion of the GGGGCC hexanucleotide in the non-coding region of represents the most common cause of familial amyotrophic lateral sclerosis. The objective was to describe and analyse the clinical...
12.
Dorst J, Weydt P, Brenner D, Witzel S, Kandler K, Huss A, et al.
EBioMedicine
. 2023 Mar;
90:104521.
PMID: 36917918
Background: The emergence of potentially effective new therapies for genetic forms of amyotrophic lateral sclerosis (ALS) necessitates the identification of biomarkers to facilitate early treatment, prior to the onset of...
13.
Catanese A, Rajkumar S, Sommer D, Masrori P, Hersmus N, Van Damme P, et al.
Brain
. 2023 Mar;
146(9):3770-3782.
PMID: 36883643
Amyotrophic lateral sclerosis is a fatal and incurable neurodegenerative disease that mainly affects the neurons of the motor system. Despite the increasing understanding of its genetic components, their biological meanings...
14.
Maier A, Boentert M, Reilich P, Witzel S, Petri S, Grosskreutz J, et al.
Neurol Res Pract
. 2022 Dec;
4(1):60.
PMID: 36522775
Background: The ALS Functional Rating Scale in its revised version (ALSFRS-R) is a disease-specific severity score that reflects motor impairment and functional deterioration in people with amyotrophic lateral sclerosis (ALS)....
15.
Xia K, Witzel S, Witzel C, Klose V, Fan D, Ludolph A, et al.
Eur J Neurol
. 2022 Sep;
30(1):87-95.
PMID: 36169607
Background And Purpose: Growing evidence shows that ALS patients feature a disturbed energy metabolism. However, these features have rarely been investigated in the presymptomatic stage. Methods: A total of 60...
16.
Witzel S, Mayer K, Oeckl P
Curr Opin Neurol
. 2022 Aug;
35(5):699-704.
PMID: 35942674
Purpose Of Review: Amyotrophic lateral sclerosis (ALS) is an incurable, devastating neurodegenerative disease. Still, the diagnosis is mainly based on clinical symptoms, and the treatment options are strongly limited. However,...
17.
Witzel S, Wagner M, Zhao C, Kandler K, Graf E, Berutti R, et al.
Neurobiol Aging
. 2022 Aug;
119:117-126.
PMID: 35933239
Patients with amyotrophic lateral sclerosis (ALS) show substantial differences in disease progression and survival. However, the genetic contribution to the extremes of this spectrum remains poorly characterized. We unbiasedly selected...
18.
Dorst J, Doenz J, Kandler K, Dreyhaupt J, Tumani H, Witzel S, et al.
J Neurol Neurosurg Psychiatry
. 2022 Jan;
93(3):298-302.
PMID: 35022317
Objective: There is growing evidence that the course of amyotrophic lateral sclerosis (ALS) may be influenced beneficially by applying high-caloric food supplements (HCSs). However, it is unknown which composition of...
19.
Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch J, Sarikidi A, et al.
JAMA Neurol
. 2022 Jan;
79(2):121-130.
PMID: 35006266
Importance: Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19...
20.
Kandler K, Witzel S, Eder K, Rothenbacher D, Nagel G, Peter R, et al.
J Neurol Neurosurg Psychiatry
. 2021 Oct;
93(5):563-565.
PMID: 34667101
No abstract available.